Browsing Tag
Cycle Pharmaceuticals
2 posts
What is HARLIKU and how will Cycle’s FDA-approved AKU drug help patients starting July 2025?
Cycle Pharmaceuticals secures FDA approval for HARLIKU™, the first approved treatment for alkaptonuria (AKU); launch in the U.S. expected July 2025.
Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals
In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals…